^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Beta radiation emitter

    Related drugs:
    18h
    131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 --> Sep 2027 | Trial primary completion date: Oct 2029 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
    19h
    Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (clinicaltrials.gov)
    P1/2, N=2, Terminated, Ariceum Therapeutics GmbH | N=50 --> 2 | Trial completion date: Dec 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Study terminated due to strategic business decisions.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Zynyz (retifanlimab-dlwr) • SOMther (lutetium-177 DOTA satoreotide)
    21h
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Novartis Pharmaceuticals | N=140 --> 24
    Enrollment change
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    21h
    PSMACare: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=80 --> 46
    Enrollment closed • Enrollment change
    |
    FOLH1 positive
    |
    Xtandi (enzalutamide) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=40, Completed, Chengdu New Radiomedicine Technology Co. LTD. | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Oct 2025 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    3d
    DOORwaY90: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, Sirtex Medical | Trial completion date: Dec 2026 --> Sep 2026
    Trial completion date
    |
    SIR-Spheres (yttrium-90 microspheres)
    4d
    Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    temozolomide • AAA603
    4d
    NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SSTR2 (Somatostatin Receptor 2) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate) • AAA603
    4d
    Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients (clinicaltrials.gov)
    P1, N=132, Recruiting, Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    5d
    INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov)
    P=N/A, N=51, Recruiting, Boston Scientific Corporation
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    5d
    [177Lu]Lu-AKIR001 First-in-human Study (clinicaltrials.gov)
    P1, N=15, Recruiting, Karolinska University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF wild-type
    6d
    A real-world study of 177Lu-PSMA-617 in the treatment of mCRPC (ChiCTR2500114390)
    P=N/A, N=20, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)